Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan

OBJECTIVE: To compare the real-world effectiveness and costs of eribulin to those of capecitabine in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes. METHODS: This study extracted data from the Health and Welfare Database in Taiwan to identify MBC patients, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yu-Ju, Kuo, Chun-Nan, Ko, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972983/
https://www.ncbi.nlm.nih.gov/pubmed/33706025
http://dx.doi.org/10.1016/j.breast.2021.02.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972983/
https://www.ncbi.nlm.nih.gov/pubmed/33706025
http://dx.doi.org/10.1016/j.breast.2021.02.011

Ejemplares similares